Lupin gets establishment inspection report from USFDA for its Nagpur facility

Earlier in May, in a regulatory filing Lupin had said that the US health regulator had completed inspection of the Nagpur facility without making any observations.

Press Trust of India August 24, 2018 15:27:13 IST
Lupin gets establishment inspection report from USFDA for its Nagpur facility

New Delhi: Drug firm Lupin on Friday said it has received an establishment inspection report (EIR) from the US health regulator after the successful inspection of its Nagpur facility.

Lupin gets establishment inspection report from USFDA for its Nagpur facility

Representational image. Getty images.

The plant was inspected by the United States Food and Drug Administration (USFDA) in May 2018, Lupin said in a filing to BSE.

Commenting on the development, Lupin MD Nilesh Gupta said, "The successful completion of the Nagpur facility inspection is a positive development as we continue our journey to meet and exceed international regulatory standards."

Earlier in May, in a regulatory filing Lupin had said that the US health regulator had completed inspection of the Nagpur facility without making any observations.

Shares of Lupin were on Friday trading at Rs 903 per scrip on BSE, down 0.07 percent from its previous close.

Updated Date:

Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply

also read

Biocon Biologics receives EIR from USFDA for two manufacturing facilities in Bengaluru
Business

Biocon Biologics receives EIR from USFDA for two manufacturing facilities in Bengaluru

Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., said on Thursday it has received the Establishment Inspection Report (EIR) from the USFDA (the United States Food and Drug Administration) for the pre-approval inspection at two of its biologics manufacturing facilities in Bengaluru

Sun Pharma receives EIR for its crucial Halol plant in Gujarat, US health regulator clears drug major
Business

Sun Pharma receives EIR for its crucial Halol plant in Gujarat, US health regulator clears drug major

Sun Pharmaceutical Industries said it has received establishment inspection report (EIR) from US health regulator for its Halol facility in Gujarat

Natco Pharma says USFDA clears inspection of its chemical division unit in Chennai
Business

Natco Pharma says USFDA clears inspection of its chemical division unit in Chennai

The USFDA released a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed